TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7522379

Group type: EXPERIMENTAL
Intervention: 10% HES 200/0.5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.6‐0.66
Number of subjects: 30
Study: 3288846

Group type: EXPERIMENTAL
Intervention: Hormone substitution therapy with 17 beta‐oestradiol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study: 239800

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control baseline conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological stress
Number of subjects: 0
Study: 31977010

Group type: EXPERIMENTAL
Intervention: CTCA
Number of subjects: 3755

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3755
Study: 31620079

Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation (FMT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no FMT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 42
Study: 28444240

Group type: EXPERIMENTAL
Intervention: tOPV
Number of subjects: 614

Group type: COMPARATOR
Intervention: IPV
Number of subjects: 614
Study: 23253638

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 8468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8468
Study: 23235499

Group type: EXPERIMENTAL
Intervention: Automated Voice Response (AVR) system alone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: AVR with strategies to manage symptoms and adherence
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: AVR with strategies to manage adherence
Number of subjects: 119

Group type: COMPARATOR
Intervention: AVR intervention alone
Number of subjects: 119
Study: 21240480

Group type: EXPERIMENTAL
Intervention: Aerochamber Plus (AP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Volumatic (VM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Synchro‐Breathe (SB)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Evohaler pMDI (EH)
Number of subjects: 17
Study: 17329954

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with sagittal plane correction using posterior instrumentation (3rd generation instrumentation system transpedicular screws)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Additional reduction of anterior slippage
Number of subjects: 40
Study: 12656701

Group type: EXPERIMENTAL
Intervention: gonadotropin‐releasing hormone agonist/estradiol group (n = 9)
Number of subjects: 21

Group type: COMPARATOR
Intervention: gonadotropin‐releasing hormone agonist/placebo group (n = 12)
Number of subjects: 21
Study: 11152083

Group type: EXPERIMENTAL
Intervention: Culturally-sensitive modifications to the Duke University Rice Diet (1000-calorie/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 1540452

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of clonidine and bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 4087288

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type B behavior pattern
Number of subjects: 0
Study: 31009438

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control - no stretching (CON)
Number of subjects: 18
Study: 30536149

Group type: EXPERIMENTAL
Intervention: RECAPP‐XPR application
Number of subjects: 273

Group type: COMPARATOR
Intervention: Snapchat application
Number of subjects: 273
Study: 30039905

Group type: EXPERIMENTAL
Intervention: Delayed loading with 45 Ncm insertion torque (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate loading with above 65 Ncm insertion torque (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All-on-4 concept (control for comparison)
Number of subjects: 30
Study: 27470610

Group type: EXPERIMENTAL
Intervention: Persuasive communication
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Action plan
Number of subjects: 129

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 129
Study: 25256937

Group type: EXPERIMENTAL
Intervention: 5.2 μg of rhFSH
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 6.9 μg of rhFSH
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 8.6 μg of rhFSH
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 10.3 μg of rhFSH
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 12.1 μg of rhFSH
Number of subjects: 265

Group type: COMPARATOR
Intervention: 11 μg (150 IU) of follitropin alfa
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: rhFSH (various doses)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: rhFSH (highest doses)
Number of subjects: 265
Study: 22733160

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) therapy with 11.25 mg leuprorelin acetate
Number of subjects: 109

Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 109
Study: 19951314

Group type: EXPERIMENTAL
Intervention: Fenwal Amicus Crescendo (AC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CaridianBCT Trima Accel (TA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Male donors greater than 88 kg using TA
Number of subjects: 91
Study: 15722066

Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg of ethinylestradiol and 120 microg of etonogestrel daily)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Combined oral contraceptive (150 microg of levonorgestrel and 30 microg of ethinylestradiol)
Number of subjects: 1030
Study: 12432044

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 10500014

Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g twice daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cellulose placebo
Number of subjects: 34
Study: 8689216

Group type: EXPERIMENTAL
Intervention: Positive cytology results from abdominal washings
Number of subjects: 535

Group type: COMPARATOR
Intervention: Negative cytology results from abdominal washings
Number of subjects: 535
Study: 1994013

Group type: EXPERIMENTAL
Intervention: Systematic outreach and screening programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy outcome measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing clinic development
Number of subjects: 0
Study: 7152078

Group type: EXPERIMENTAL
Intervention: Meptazinol 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31675992

Group type: EXPERIMENTAL
Intervention: Recruitment video for staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported data collection prior to randomisation and treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of participant dropout due to delays in treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triangulation of data sources for follow-up
Number of subjects: 0
Study: 29909282

Group type: EXPERIMENTAL
Intervention: Cooking bag
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blade tenderizer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Marinade
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-temperature cooking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Roast beef (cooked using culinary processes)
Number of subjects: 40
Study: 26814240

Group type: EXPERIMENTAL
Intervention: HYD coarse particles 60 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HYD fine particles 60 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hydrocodone powder 60 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 31
Study: 25453486

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 0.05-0.12mg/kg/day (6-12 years: 1-4mg/day; 13-17 years: 1-7mg/day)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 10-100mg/day
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 21978796

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study: 19843053

Group type: EXPERIMENTAL
Intervention: Palosuran 125 mg b.i.d. for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17264714

Group type: EXPERIMENTAL
Intervention: 800 mg daily dexibuprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 mg daily aspirin
Number of subjects: 12
Study: 15891954

Group type: EXPERIMENTAL
Intervention: Pramlintide + insulin
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo + insulin
Number of subjects: 477
Study: 11976561

Group type: EXPERIMENTAL
Intervention: Metformin treatment after one month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 10
Study: 9670263

Group type: EXPERIMENTAL
Intervention: Intraarterial hepatic chemotherapy (IAHC) using IA FUDR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarterial hepatic chemotherapy (IAHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New protocols and combinations with systemic chemotherapy
Number of subjects: 0
Study: 7614642

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg.kg‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone (4 mg.kg‐1)
Number of subjects: 50
Study: 2212090

Group type: EXPERIMENTAL
Intervention: CHX-rinse (0.12%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CHX-irrigation (0.06%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo-irrigation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo-rinse
Number of subjects: 44
Study: 484813

Group type: EXPERIMENTAL
Intervention: Methohexitone 0.5 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Etomidate 0.067 mg/kg
Number of subjects: 14
Study: 30682557

Group type: EXPERIMENTAL
Intervention: Severity of alcohol use problems
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lifetime trauma exposure
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Higher manic symptom scores
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Severity of alcohol and drug use problems
Number of subjects: 243

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 243
Study: 29061010

Group type: COMPARATOR
Intervention: Remifentanil 0.1 μg·kg(‐1)·min(‐1) (Group S)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg·kg(‐1)·min(‐1) (Group L)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 μg·kg(‐1)·min(‐1) + lappaconitine 8 mg (Group G)
Number of subjects: 120
Study: 25830364

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 36
Study: 24499494

Group type: EXPERIMENTAL
Intervention: 10 mg NRL001 (2 g suppository)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21813856

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified biscuits (FB)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Albendazole plus FB
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: FB
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510

Group type: COMPARATOR
Intervention: Non-fortified biscuits
Number of subjects: 510
Study: 19901414

Group type: EXPERIMENTAL
Intervention: Provisional stenting (PS)
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Complex stenting strategy (CS)
Number of subjects: 1641
Study: 17207668

Group type: EXPERIMENTAL
Intervention: BTX‐A plus OT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BTX‐A alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OT alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 80
Study: 15258003

Group type: EXPERIMENTAL
Intervention: 5.00 dollars incentive
Number of subjects: 199
Study: 11526365

Group type: COMPARATOR
Intervention: b-blockade (Metoprolol)
Number of subjects: 3991
Study: 9085171

Group type: EXPERIMENTAL
Intervention: Contrast media containing ulinastatin (UST)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Contrast media containing prednisolone (PDN)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination of UST and PDN
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 8519040

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (ECA) 325 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buffered aspirin (BA) 325 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plain aspirin (ASA) 325 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Duodenal mucosa injury (BA, ECA, ASA, placebo)
Number of subjects: 80
Study: 3735414

Group type: EXPERIMENTAL
Intervention: Imipramine 100 mg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 31752595

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia (CBT-I)
Number of subjects: 5
Study: 31041716

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (TAS102)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29420925

Group type: EXPERIMENTAL
Intervention: 3 g of HMB-FA
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study: 26959860

Group type: EXPERIMENTAL
Intervention: Threat agency assigned to diabetes
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Prevention agency assigned to humans
Number of subjects: 422

Group type: COMPARATOR
Intervention: Threat agency assigned to humans
Number of subjects: 422

Group type: COMPARATOR
Intervention: Prevention agency assigned to recommended behaviors
Number of subjects: 422
Study: 24684675

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral hernia repair (LVHR) in Tx/IS patients
Number of subjects: 101

Group type: COMPARATOR
Intervention: Laparoscopic ventral hernia repair (LVHR) in non-IS patients
Number of subjects: 101
Study: 24347766

Group type: EXPERIMENTAL
Intervention: Teaching module with video demonstration and practice session before OSPE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with video demonstration and practice session after OSPE
Number of subjects: 40
Study: 20415603

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18764978

Group type: EXPERIMENTAL
Intervention: Controlled-release levodopa (CR-LD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Immediate-release levodopa (IR-LD)
Number of subjects: 14
Study: 11785993

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 10141
Study: 10323085

Group type: EXPERIMENTAL
Intervention: AgNOR method staining and morphometric analysis
Number of subjects: 50
Study: 7641909

Group type: EXPERIMENTAL
Intervention: Minimal monitoring at transport clinic (1.5 +/- 0.8 US measurements)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional monitoring at satellite clinics (2.8 +/- 0.9 US measurements)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Minimal monitoring at transport clinic
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional monitoring at satellite clinics
Number of subjects: 200
Study: 2665657

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b conjugate vaccine (standard dose)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b conjugate vaccine (low dose)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Diphtheria, pertussis, and tetanus and polio vaccines only (Control)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Unimmunized infants
Number of subjects: 103
Study: 1000148

Group type: EXPERIMENTAL
Intervention: Extra interviews designed to increase understanding of illnesses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extra placebo interviews about hospital stay
Number of subjects: 0
Study: 30357310

Group type: EXPERIMENTAL
Intervention: Tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard interval 5-fluorouracil/E/C and D
Number of subjects: 0
Study: 27129585

Group type: EXPERIMENTAL
Intervention: Semi-reduction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Full-reduction
Number of subjects: 39

Group type: COMPARATOR
Intervention: No reduction (control)
Number of subjects: 39
Study: 25814042

Group type: EXPERIMENTAL
Intervention: Tobramycin aerosol (150mg/3ml) administered via the Easynose® device
Number of subjects: 55

Group type: COMPARATOR
Intervention: Isotonic saline aerosol
Number of subjects: 55
Study: 23802927

Group type: EXPERIMENTAL
Intervention: Stage‐matched nursing and community intervention (SMN+CI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Community intervention (CI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 21851204

Group type: EXPERIMENTAL
Intervention: Nutritional counselling group (NCG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ad libitum group (ALG)
Number of subjects: 21
Study: 20168104

Group type: EXPERIMENTAL
Intervention: Moxibustion (stimulating acupoint BL 67 daily for 2 weeks)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Expectant management care (Control)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 212
Study: 17251178

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol combination
Number of subjects: 177

Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 177
Study: 15517934

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 32

Group type: COMPARATOR
Intervention: No-EPO (blood transfusions)
Number of subjects: 32
Study: 11182036

Group type: EXPERIMENTAL
Intervention: BCG instillation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Doxorubicin instillation
Number of subjects: 20
Study: 9447537

Group type: EXPERIMENTAL
Intervention: Topical lidocaine and prilocaine cream (1 to 1.25 gm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Zinc oxide placebo
Number of subjects: 13
Study: 7942935

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 92
Study: 2847676

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at high pressor dose (to increase diastolic pressure by 25 mmHg) in healthy volunteers
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in healthy subjects
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in patients with mild essential hypertension
Number of subjects: 11
Study: 30433852

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin and radiation twice a day (FCT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Once daily radiation plus gemcitabine (GD)
Number of subjects: 66
Study: 26838529

Group type: EXPERIMENTAL
Intervention: SMOFlipid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 25816746

Group type: EXPERIMENTAL
Intervention: 1WS: one 60‐min supervised session/week
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 3WS: three 20‐min supervised sessions/week
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 9WS: nine 7‐min supervised sessions/week
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 3MS: three 20‐min sessions/week with minimal supervision
Number of subjects: 573

Group type: COMPARATOR
Intervention: REF: reference group without training
Number of subjects: 573
Study: 23744847

Group type: EXPERIMENTAL
Intervention: HES group (hydroxyethyl starch 130/0.4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gelo group (gelatin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HES group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gelo group
Number of subjects: 60
Study: 19207485

Group type: EXPERIMENTAL
Intervention: HybenX
Number of subjects: 63

Group type: COMPARATOR
Intervention: Salicept
Number of subjects: 63
Study: 18021576

Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Stress Echo
Number of subjects: 898

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 898
Study: 15098804

Group type: EXPERIMENTAL
Intervention: HRT before WHI (July 9, 2001 - January 9, 2002)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: HRT after WHI (July 9, 2002 - January 9, 2003)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pre-WHI group (randomized)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Post-WHI group (randomized)
Number of subjects: 98
Study: 11565624

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-7, 100 mg on days 8-14)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg on days 1-7, 40 mg on days 8-14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9630155

Group type: EXPERIMENTAL
Intervention: Single transperineal injection of botulinum toxin
Number of subjects: 5
Study: 7943829

Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg.kg-1
Number of subjects: 256

Group type: COMPARATOR
Intervention: metoclopramide 0.5 mg.kg-1
Number of subjects: 256

Group type: COMPARATOR
Intervention: droperidol 0.075 mg.kg-1
Number of subjects: 256

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 256